Moderna does one better than Pfizer/BioNTech; touts 94.5% efficacy for its Covid vaccine
The company is the second this month to report promising results for a Covid-19 vaccine even as the virus rages across the U.S.
The company is the second this month to report promising results for a Covid-19 vaccine even as the virus rages across the U.S.
To make vaccination work, we must reach out to the naturally cautious – a bigger proportion than you might assume Coronavirus – latest updates See […]
Uğur Şahin ‘very confident’ vaccine candidate developed with Pfizer will cause big reduction in cases Coronavirus – latest updates See all our coronavirus coverage The […]
Better to build social solidarity than to dismiss reluctance to be immunised as ignorance Coronavirus – latest updates See all our coronavirus coverage “If a […]
Qiagen Launches Portable Digital SARS-CoV-2 Antigen Test in the US Published: Nov 13,2020 | Tags: Antigen Test, Digital, Launches, Portable, Qiagen, SARS-CoV-2, US GSK and […]
Exclusive: Ugur Şahin says he and Pfizer CEO received results night before announcement Coronavirus – latest updates See all our coronavirus coverage The scientist behind […]
Exclusive: BioNTech’s CEO Uğur Şahin says he is confident vaccine can ‘bash the virus over the head’ Coronavirus – latest updates See all our coronavirus […]
The pharmaceutical industry has long made exorbitant profits by free-riding on research carried out by the public sector Hooray for Pfizer! As news of a […]
The European Union has ordered 300 million doses of BioNTech/Pfizer’s COVID-19 vaccine following this week’s landmark announcement that it was effective in more than 90% […]
Shots: The companies sign an agreement with the EC to supply 200M doses of BNT162b2 mRNA-based vaccine candidate against SARS-CoV-2 to EU member states, with […]
Despite the Pfizer breakthrough, social distancing and remote working won’t disappear overnight Coronavirus – latest updates See all our coronavirus coverage The news this week […]
Shots: The P-lll JADE REGIMEN study involves assessing of Abrocitinib (100/ 200mg) vs PBO in 1233 patients aged ≥ 12 yrs. in a ratio (1:1:1) […]
The lion’s share of the potential Pfizer vaccine is already claimed by high-income nations The news that joint efforts by the US pharmaceutical company Pfizer […]
News of positive results from Pfizer’s Covid-19 vaccine is heartening but historically, important scientific announcements about vaccines are made through peer-reviewed medical research papers that […]
Pfizer said sale of shares by Albert Bourla was automated under plan set up in August Coronavirus – latest updates See all our coronavirus coverage […]
Roll-Royce gave an eye-catching pitch but the economics of nuclear power needs further inspection An energy white paper is in the offing, so consider Rolls-Royce’s […]
China’s ambition to build a nuclear plant in Essex will likely fail on national security grounds The new national security and investment bill, aiming to […]
Promising clinical data from Pfizer and BioNTech help the index to a £28bn one-day gain Optimism that a mass rollout of Covid-19 vaccines will lead […]
Johnson & Johnson and AstraZeneca pledged to make their vaccines available on a not-for-profit basis Coronavirus – latest updates See all our coronavirus coverage The […]
Europe and US create vast facilities for Covid-19 vaccine but poorer nations lack infrastructure say experts Coronavirus – latest updates See all our coronavirus coverage […]
At last, there is hope of an end to this pandemic. Scientists appear to have performed an amazing feat, the rest of us must do […]
The UK usually has a high take-up for vaccines, experts say, but there are fears over misinformation and scepticism Coronavirus: anti-vaxxers seek to discredit Pfizer’s […]
Readers respond to news that an interim analysis has shown Pfizer/BioNTech’s vaccine candidate was 90% effective in protecting people from transmission of the virus in […]
Pfizer’s preliminary results are a huge development, although hurdles still lie ahead Dr Charlotte Summers is a lecturer in intensive care medicine at the University […]
Interim results show vaccine to be 90% effective, but findings have not been peer-reviewed, Australia has only secured enough for five million people, and there […]
But the news highlighted divergences in fortunes across sectors during the pandemic Global stock markets surge after Pfizer Covid vaccine news Nils Pratley: ‘A great […]
The news sent the stock market soaring as it represents a key milestone in developing and distributing a vaccine for the virus. Still public confidence […]
Interim trial results are encouraging as scientists welcome news Coronavirus – latest updates See all our coronavirus coverage It is not yet the end of […]
Early results from phase 3 trial look promising but there are still many questions to be answered Coronavirus – latest updates See all our coronavirus […]
FTSE 100 jumps as Pfizer and BioNTech report coronavirus vaccine is 90% effective Coronavirus – latest updates See all our coronavirus coverage Global stocks have […]
As the death toll from COVID19 inexorably mounts, Pfizer and BioNTech have announced that their COVID-19 vaccine candidate is more than 90% effective at countering […]
Mylan’s $12 billion takeover of Pfizer’s Upjohn unit has been cleared by the US authorities, but on the condition that the two companies divest various […]
The third quarter of 2020 was flooded with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisitions, […]
Pfizer could be just a few months away from getting FDA approval for its JAK1 inhibitor abrocitinib in atopic dermatitis, a drug that CEO Albert […]
Gamified digital therapeutics firm Sidekick Health has raised $20 million in a Series A funding round, which it plans to use to develop its product […]
Pfizer is one of the front-runners in the race to approve a COVID-19 vaccine but the US company has had to weather lower revenues for […]
Moderna is close to completing its phase 3 trial of COVID-19 vaccine candidate mRNA-1273 after completing recruitment of the 30,000 subjects in the trial. It’s […]
Immunology is an important branch of science which deals with the study of the immune system. The immune system is a highly regulated and balanced […]
Merck & Co has built more momentum behind its attempt to depose Pfizer’s blockbuster pneumococcal conjugate vaccine Prevnar 13, with two new phase 3 trials […]
Pfizer now has hundreds of thousands of doses of BioNTech’s COVID-19 vaccine coming off the production line at a facility in Belgium, ready for delivery […]
The UK government has signed a contract to develop a controversial COVID-19 human challenge trial, where participants will be deliberately infected in a controlled environment […]
Pfizer said it will wait until after the US election to file its COVID-19 vaccine with the US regulator, as it waits for important safety […]
Novartis’s Luxturna (voretigene neparvovec) Receives Health Canada Approval as the First Gene Replacement Therapy for Inherited Retinal Disease Published: Oct 15, 2020 | Tags: approval, […]
The US FDA has approved 6 NDAs in Sept 2020, leading to treatments for patients and advances in the health care industry. The Center for […]
Shots: Pfizer will continue to provide sales and marketing support and health system support for Cologuard through the end of 2022 and 2021, respectively. Exact […]
Shots: The Rolling Submission is based on the preliminary results from pre-clinical and early clinical studies in adults, which shows that BNT162b2 triggers the production […]
The European Medicines Agency has begun a second “rolling review” of a potential coronavirus vaccine jointly developed by BioNTech and Pfizer, setting up a race […]
Shots: Pfizer to sponsor & conduct P-Ib/II study evaluating the safety, tolerability, and preliminary efficacy of dual regimen and will assume costs of study & […]
Sobi & Selecta Report Results of SEL-212 in P-II COMPARE Study for Chronic Refractory Gout Published: Oct 1, 2020 | Tags: Chronic Refractory Gout, COMPARE […]
1. Taysha Gene Therapies’ TSHA-101 Receives the US FDA’s Orphan Drug Designation and Rare Pediatric Disease Designation for GM2 Gangliosidosis Published: Aug 27, 2020 | […]
The companies also said their Phase II/III study, slated to enroll about 30,000 participants, had already dosed more than 11,000.
1. BioMarin Reports NDA Submission to the US FDA for Vosoritide to Treat Children with Achondroplasia Published: Aug 20, 2020 | Tags: BioMarin, Reports, NDA, […]
New insights into smell and taste loss symptoms, artificial intelligence and further encouraging data from a vaccine candidate hit the headlines this week as the […]
Pfizer and BioNTech have said their COVID-19 vaccine could be ready for regulators to review by October and approved by the end of the year […]
Shots: The companies have shared additional P-I safety and immunogenicity data from their ongoing US study of the BNT162b2 against SARS-CoV-2, which has advanced into […]
1. Roche’s Evrysdi (risdiplam) Receives the US FDA’s Approval for SMA in Adults and Children Published: Aug 10, 2020 | Tags: Roche, Evrysdi, risdiplam, Receives, US, […]
Sequent Research Ltd Recruitment August 2020. SeQuent is looking towards the future with courage and confidence, because of the critical role it can play to help make […]
Gilead Sciences had said in its second-quarter earnings that it would partner with companies in North America, Europe and Asia to manufacture the antiviral drug, […]
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective […]
Pfizer has taken a big step towards positioning Lorbrena as a worthy heir to its big-selling Xalkori drug in lung cancer, after beating its parent […]
1. Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant to Manufacture and Supply AXO-Lenti-PD for Parkinson’s Disease Published: Jul 31, 2020 | Tags: Oxford […]
Financial terms of the deal were not disclosed, but it follows a $1.95 billion contract between the two companies and the U.S. government. Assuming clinical […]
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has […]
NICE has said a combination of Merck KGaA’s Bavencio and Pfizer’s Inlyta should be available as a first line option for kidney cancer patients for […]
Pfizer has cautiously upped its guidance despite second quarter figures showing a slip in sales and profitability compared with the same period last year. Revenues […]
The companies said they had started a Phase II/III trial BNT162b2. The news comes the day after Moderna announced the launch of its Phase III […]
Shots: The companies commence global (Ex- China) P-II/III study to evaluate a modRNA candidate (BNT162b2, 30µg dose level in a 2 dose regimen) from their […]
1. Gilead and Galapagos’ Jyseleca (filgotinib) Receive the CHMP’s Positive Opinion for Moderate to Severe Rheumatoid Arthritis Published: Jul 24, 2020 | Tags: Gilead, Galapagos, Jyseleca, […]
The US government has agreed to pay Pfizer and BioNTech $1.95 billion to secure access to 100 million doses of their coronavirus vaccine on approval, […]
The companies will supply 100 million doses of the vaccine by the end of the year, and the government will have the option to acquire […]
Concerns have emerged about access to some potential COVID-19 vaccines after pharma executives from three companies said they expect to make profits from their products […]
Shots: The companies reported that most advanced of four COVID-19 vaccine candidates from their BNT162 mRNA-based vaccine program demonstrated the ability to elicit high SARS-CoV-2 […]
The UK has secured 90 million doses of two different COVID-19 vaccines from BioNTech/Pfizer and Valneva, with an option of 40 million doses if they check out in trials. There […]
1. Eli Lilly Reports Results of Mirikizumab in P-III OASIS-2 Study to Treat Moderate to Severe Plaque Psoriasis Published: Jul 17, 2020 | Tags: Eli Lilly, […]
The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs […]
Shots: NCCN and Pfizer have issued an open RFP that develop and validate enduring approaches to improve the safe, effective, and efficient adoption of biosimilars […]
The companies anticipate releasing more clinical data from the BNT162 messenger RNA vaccine program and potentially starting a 30,000-participant Phase IIb/III study this month.
The company said Tuesday that a final analysis of its Phase IIb/III study of cabotegravir showed greater efficacy in HIV prevention than Gilead’s Truvada. The […]
Copyright © 2024 | WordPress Theme by MH Themes